PWID carry the highest burden of hepatitis C virus (HCV) infection, with almost half of PWID worldwide living with HCV.\(^1-5\) Injection drug use is the main route of transmission in middle- and high-income regions.\(^1-5\) In the United States, HCV incidence tripled from 2010 to 2015, primarily because of opioid injection.\(^6\) High levels of HCV treatment and cure for PWID can reduce HCV incidence and prevalence.\(^7-10\) Compelling evidence demonstrates that direct-acting antiviral (DAA) agents are effective for PWID. Two recent meta-analyses indicate high sustained virological response (SVR) rates among PWID regardless of whether they were receiving opioid agonist therapy (OAT).\(^11,12\) For all of these reasons, international guidelines support prioritization and HCV treatment scale-up for this population.\(^13,14\)

Nevertheless, the HCV cascade to cure has not reached PWID in sufficient numbers.\(^15\) Barriers are many and include, at the patient level, stigma, difficulty navigating conventional health settings, and fragmented care.\(^16\) At the provider level, there is reluctance to treat PWID.\(^17,18\) At the system level, prescribing restrictions may bar drug-involved patients from receiving DAAs.\(^19\) Delivering all elements of care at a single site, as well as streamlining care to reduce time from infection to cure, may be accomplished with colocation of HCV and addiction care. Integrated, multidisciplinary care unites expertise in both HCV and addiction.

Colocation can be physical. There are a growing number of successful models of HCV care for PWID, on-site at accessible venues welcoming to this population, or where PWID may congregate or are already accessing services, including needle syringe programs (NSP) and centers for people experiencing homelessness.\(^20,21\) Colocation at OAT programs is critical, because 83% of PWID mainly inject opioids.\(^1\) OAT, the fundamental treatment for opioid use disorder (OUD), reduces illicit opioid use, craving, and death.\(^22\) With integrated OAT/HCV care, a population already engaged in treatment for the chronic disease of addiction is available for DAAs. OAT facilitates HCV screening, treatment uptake, and SVR, and can reduce incidence and reinfection.\(^1,23-25\) Colocated OAT can improve retention in HCV care. Without a vaccine,
prevention benefits are greatest when DAAs are delivered with OAT and high-coverage NSP.\textsuperscript{26-28}

In the United States, federal regulations limit access to the two OATs, methadone (\(\mu\)-receptor full agonist) and buprenorphine (\(\mu\)-receptor partial agonist often paired with the antagonist naloxone). For methadone, this became law with the 1974 Narcotic Addict Treatment Act, mandating that for methadone maintenance, patients must attend a federally licensed clinic. This created a methadone clinic system organizationally and often physically separate from mainstream health care.\textsuperscript{29} Methadone maintenance programs are highly structured. A physician evaluates patients; then nurses administer methadone daily under observation. Take-home doses, freeing patients from daily visits, are contingent on criteria, including toxicology results, time in treatment, and attendance.

The methadone clinic infrastructure can be leveraged for colocated HCV care. At minimum, there is opportunity for a supportive environment for drug-involved populations, that is, staff familiar with psychosocial needs not typically addressed in tertiary care and a setting in which patients receive care without shame. The attendance required provides occasion for daily or at least frequent contact with clinicians, enhancing support and establishing the option of directly observed therapy to bolster DAA adherence. Prevention incorporates providing naloxone, sterile injection equipment, hepatitis A and B vaccination, and HIV pre-exposure prophylaxis. Services may include counseling, peer support, and housing assistance. This lays the foundation for universal HCV “Test to Treat,” beginning with opt-out HCV screening on entry into OAT treatment, via the most efficient method available (dried blood spot sampling, point-of-care finger-stick HCV RNA testing, or venous HCV antibody with reflex HCV RNA viral load). The path to cure is accelerated with simplified pretreatment assessment, HCV education, serum biomarkers to stage fibrosis, and minimal on-treatment monitoring. Posttreatment care encompasses obtaining SVR, management of cirrhosis, ongoing harm reduction, and routine testing for reinfection. Facilitators include a low-threshold, flexible configuration respectful of patients’ preferences, accommodating walk-in visits, and the ability to be a place of last resort where patients can remain in HCV care no matter the number of late or missed visits. Ideally, the bedrock of this approach is primary care, plus psychiatry and care for comorbidities such as HIV. A challenge in the United States is that typically, methadone clinics are not ambulatory care centers and do not provide primary care.

A representative model of ideal, comprehensive health care for PWID under one roof is Switzerland’s Arud (Fig. 1).\textsuperscript{30} Arud is a primary care–based addiction medicine institute with integrated HCV and psychiatric services, delivered by a multidisciplinary team. Arud provides prevention and treatment for the broader scope of infectious diseases afflicting PWID, and supplies free sterile injection equipment. OUD therapy includes methadone, buprenorphine, long-acting morphine, and heroin-assisted treatment (HAT). In 1994, Switzerland became the first country to establish a widespread, government-funded program of heroin prescription, under a policy aimed to curb overdose and HIV. HAT is designed to treat a minority of people who do not respond successfully to other therapies. Patients inject heroin under medical supervision at ARUD. To date, SVR rate is 92%; excluding treatment completers

**FIG 1** Arud, Switzerland. Colocated HCV and OUD care: a representative model of ideal, comprehensive, whole-person health care for PWID under one roof.
lost to follow-up prior to 12-week testing yields a modified intention-to-treat SVR of 97%.

How can we expand capacity in the United States given the myriad challenges to inserting HCV management into 1613 methadone clinics? One hurdle is the complicated insurance and payment structure with insufficient reimbursement for HCV outpatient services without supporting income from endoscopy, colonoscopy, and radiology. This can make HCV care unsustainable at nonprofit and public methadone clinics when state and federal support for OUD does not cover HCV care. Meanwhile, the for-profit methadone programs increase at nonprofit and public methadone clinics when state and federal support for OUD does not cover HCV care. Virtual colocation can aid in HCV treatment rollout. Telemedicine uses technological advances to bridge geographic separation between the HCV expert and methadone clinic with two-way videoconferencing between patient and specialist. This imports HCV management into locales convenient and familiar to patients, but lacking HCV expertise, infrastructure, and resources. For example, off-site hepatologist Dr. Andrew Talal provided telemedicine-based HCV care to New York City methadone patients via the PET-C (Prevention, Evaluation and Treatment of HCV) Study. At their methadone clinic, patients were screened for HCV and shown a video on telehealth. Patients had initial evaluation and HCV discussion with pretreatment laboratory tests collected on-site, including FibroSure to stage fibrosis. The specialist documented the visit in the electronic health record, collaborating with an on-site physician assistant, and submitted a bill. DAAAs were dispensed with daily methadone. SVR was 93%. Dr. Talal is now conducting a randomized trial comparing telemedicine with usual care at 12 methadone clinics throughout New York state.

To achieve HCV elimination, PWID must be engaged in care. HCV and OAT care plus NSP provision are the necessary trifecta to facilitate prevention and the path to cure via physical or virtual colocation. Further research to inform the design, optimize outcomes, and evaluate these embedded care models is needed, along with attention to alternative payment and financing models. Expanding methadone availability across diverse clinical settings including primary care and integrating HCV services with methadone maintenance are key steps in the worldwide public health response to the HCV epidemic.

REFERENCES

1) Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Global Health 2017;5:e1192-e1207.
2) Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011;378:571-583.
3) Grebely J, Larney S, Peacock A. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019;114:150-166.
4) Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 2017;14:641-651.
5) Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-562.
6) Centers for Disease Control and Prevention. Viral hepatitis surveillance: United States, 2017. Available at: https://www.cdc.gov/hepatitis/statistics/2017surveillance/pdfs/2017HepSurveillanceRpt.pdf. Published November 14, 2019.
7) Iversen J, Dore GJ, Catlett B, et al. Association between rapid utilization of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol 2019;70:33-39.
8) Trickey A, Fraser H, Lim AG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study. Lancet Gastroenterol Hepatol 2019;4:435-444.
9) Hellard M, Doyle JS, Sacks-Davis R, et al. Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology 2014;59:366-369.
10) Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J Hepatol 2011;54:1137-1144.
11) Hajarizadeh B, Cunningham EB, Reid H. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018;3:754-767.
12) Graf C, Mücke MM, Peiffer KH, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: A systematic review and meta-analysis. Clin Infect Dis 2019,2019:ciz696.
13) American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2019. Available at: http://www.hcvguidelines.org/. Accessed November 15, 2019.
14) World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [Licence: CC BY-NC-SA 3.0 IGO]. Geneva: World Health Organization; 2018.
15) Grebely J, Raffa JD, Lai C, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011;18:32-41.

16) Grebely J, Oser M, Taylor LE, et al. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. J Infect Dis 2013;207(Suppl. 1):S19-S25.

17) Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: Effects on eligibility for hepatitis C treatment. Am J Addict 2011;20:312-318.

18) Batki SL, Canfield KM, Smyth E, et al. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: A case-control study. J Addict Dis 2010;29:359-369.

19) Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-223.

20) Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all. Clin Infect Dis 2013;57(Suppl. 2):S56-S61.

21) Beiser ME, Smith K, Ingemi M, et al. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy 2019;72:129-137.

22) Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550.

23) Alavian SM, Mirahmadizadeh A, Javanbakht M, et al. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 2013;13:e12411.

24) Tsui JI, Evans JL, Lum PI, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014;174:1974-1981.

25) Akiyama MJ, Lipsey D, Heo M, et al. Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clin Infect Dis 2019;2019:czs693.

26) Martin NK, Hickman M, Hutchinson S, et al. Combination interventions to prevent HCV transmission among people who inject drugs: Modelling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl. 2):S39-S45.

27) Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review. Lancet Global Health 2017;5:e1208-e1220.

28) Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane review and meta-analysis. Addiction 2018;113:545-563.

29) Samet JH, Botticelli M, Bharel M. Methadone in primary care—one small step for congress, one giant leap for addiction treatment. N Engl J Med 2018;379:7-8.

30) Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. Int J Drug Policy 2018;62:74-77.

31) Substance Abuse and Mental Health Services Administration. Opioid Treatment Program Directory. Available at: https://dpt2.samhsa.gov/treatment/directory.aspx. Published 2018. Accessed November 11, 2018.

32) Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA 2013;310:2671-2672.

33) Talal AH, Andrews P, Mcleod A, et al. Integrated, co-located, tele-medicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin Infect Dis 2019;69:323-331.

34) Socías ME, Karamouzian M, Parent S, et al. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Int J Drug Policy 2019;72:146-159.